A Phase 1b/2a Clinical Trial of Dantrolene Sodium in Patients with Wolfram Syndrome

Background. Wolfram syndrome is a rare endoplasmic reticulum disorder characterized by insulin-dependent diabetes mellitus, optic nerve atrophy, and progressive neurodegeneration. Although there is currently no treatment to delay, halt, or reverse the progression of Wolfram syndrome, preclinical studies in cell and rodent models suggest that therapeutic strategies targeting endoplasmic reticulum calcium homeostasis, including dantrolene sodium, may be beneficial. Methods: Based on the results from preclinical studies on dantrolene sodium and ongoing longitudinal studies, our group put together the first-ever clinical trial in pediatric and adult patients with Wolfram syndrome. An open-label phase 1b/2a trial design was chosen. The primary objective of the study was to assess the safety and tolerability of dantrolene sodium in adult and pediatric patients with Wolfram syndrome. Secondary objectives were to evaluate the efficacy of dantrolene sodium on residual pancreatic beta-cell functions, visual acuity, quality of life measures related to vision, and neurological functions. Results: The results indicate that dantrolene sodium is well tolerated by patients with Wolfram syndrome. Although the study was small, a select few patients seemed to have improvements in beta-cell function, which might correlate with a positive trend in other outcome measures, including visual acuity and neurological functions. Conclusion. This study justifies further investigation into using dantrolene sodium and other small molecules targeting the endoplasmic reticulum for the treatment of Wolfram syndrome.

Introduction 91 the safety and tolerability of dantrolene sodium in adult and pediatric subjects with Wolfram 137 syndrome. Secondary objectives were also to assess the effect of dantrolene sodium on residual 138 pancreatic β-cell function, visual acuity, neurological function and quality of life measures. 139 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Trial population 141
A total of 22 subjects (6-32 years old) with a genetically confirmed diagnosis of Wolfram 142 syndrome, were screened for enrollment in this study ( Figure 1B). Of this group, 21 qualified for 143 baseline laboratory and quality of life assessments in order to begin the run-in regimen of oral 144 dantrolene parallel to ongoing maintenance medications. Two subjects (11% of qualified 145 population) had to be excluded before the 6-month assessment of study outcome measures on 146 dantrolene treatment due to loss to follow-up or personal reasons. The baseline demographic and 147 clinical characteristics of the 19 subjects that completed the trial are shown in Table 1 Dantrolene was well-tolerated among pediatric subjects at a final daily dose between 0.5 mg/kg 157 and 2.0 mg/kg, with a maximun daily dose of 100 mg. The mean final daily dose in the pediatric 158 subjects was 1.25 mg/kg/day ( Figure 1C). Adults subjects tolerated dantrolene well between 50 159 mg to 100 mg daily. 5, 4, and 2 subjects tolerated 50, 75, and 100 mg of dantrolene respectively. 160 This resulted in a mean dose of 68.2 mg daily ( Figure 1D). These dosing ranges closely 161 approximated therapeutic ranges for dantrolene when used to treat spasticity 25 . 162 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

163
Adverse events were stratified into three categories based on their likelihood of being attributed 164 to the study drug. These categories included adverse events attributed directly to dantrolene, 165 events known to occur commonly in patients with Wolfram syndrome, and non-specific events 166 not easily attributed to dantrolene or Wolfram syndrome. The most common adverse dantrolene 167 related events observed in pediatric and adult subjects were mild fatigue and diarrhea. The most 168 common Wolfram syndrome related events were mild hypoglycemia, and headaches. These 169 symptoms affected at least 25% of the total study population ( Table 2). Hepatoxicity and 170 weakness, the most serious known side effects of dantrolene, were not very prevalent in our 171 study population. Elevated liver enzymes were observed in 2 subjects (11% of total population) 172 and weakness was self-reported by 4 subjects (21% of total population). Quantitative 173 assessments of strength prior to and at each subsequent trial visit after dantrolene administration 174 showed no significant loss in grip strength during 6-months of dantrolene treatment 175 (Supplementary Figure 1). No clinically significant changes in laboratory measures or in findings 176 from physical examinations were noted during enrollment in this study. No significant EKG 177 changes were observed in subjects during the run-in period or thereafter. Additionally, no subject 178 discontinued the trial regimen due to adverse effects. To assess the effect of dantrolene on glycemia and remaining β-cell function, HbA1c and 30-183 minute mixed-meal stimulated C-peptide were monitored at baseline and after 6-months of 184 dantrolene treatment ( Figure 1A). Mean HbA1c across all subjects remained stable between 185 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted October 12, 2020.
1 1 dantrolene initiation and after 6-months of treatment (7.4 ± 0.2 %, p-value 0.63). Subgroup 186 analyses of adult and pediatric subjects also demonstrated no significant change in HbA1c (7.4 187 ± 0.2 %) ( Figure 2A). Mean fasting C-peptide levels of the total study cohort also remained 188 stable during this period (0.27 ± 0.07 ng/mL at 6-months of treatment compared to 0.27 ± 0.06 189 ng/mL at baseline, p-value 0.95). At the conclusion of the study, mean stimulated C-peptide 190 levels were not significantly higher compared to the pre-treatment baseline (0.64 ± 0.14 ng/mL 191 after 6-months of treatment compared to 0.52 ± 0.10 ng/mL at baseline, p-value 0.14) (    Figure 3A). Review of these data suggested that our 215 hypothesis was correct, as subjects with higher ∆ C-peptide to begin with, tended to have a higher 216 ∆ C-peptide at 6 months and higher slope (∆∆C-peptide). To further test this relationship, we 217 performed linear regression analysis demonstrating a statistically significant (R 2 0.439, p-value 218 0.004) positive relationship between baseline ∆ C-peptide, and (∆∆C-peptide) ( Figure 3B). A 219 histogram was created to visualize the distribution of ∆ ∆ C-peptide amongst the study subjects 220 ( Figure 3C). The 0.05, 0.1, and 0.2 ng/mL cutoffs were superimposed upon this the linear 221 regression and histograms. Based on previous literature 28, 29 , we decided that the cutoff of a 222 ∆ ∆ C-peptide ≥ 0.1 ng/mL is likely to be of clinical significance, for subjects with Wolfram 223 syndrome. This fit the overall distribution of data, as 5 subjects (subject ID #4, 8, 10, 17, and 224 22), met this criterion. They represented 26.3% of the total study population. These subjects 225 included 3 adult and 2 pediatric individuals. The ∆ ∆ C-peptide ≥ 0.1 ng/mL cutoff is henceforth 226 used to classify subjects as responders versus non-responders. 227 228 As our hypothesis is that subjects with increased β cell function had a more robust response to 229 dantrolene, we set out to determine if any baseline measurement had predictive value. This could 230 help clinicians, caring for patients with Wolfram, determine if dantrolene could be beneficial. 231 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 1 3 Therefore basal, stimulated, and ∆ C-peptide data collected from subjects prior to starting 232 dantrolene were analyzed to determine which of these criteria could best be used. Histograms 233 and receiver-operator-characteristic (ROC) curves were created based on these data. A positive 234 control using ∆ ∆ C-peptide which, by design, demonstrated 100% sensitivity and specificity 235 using a ∆ ∆ C-peptide value ≥ 0.12 ng/mL was also created (Supplementary Figure 3D,H). 236 Baseline measurements of β -cell function had a modest predictive value. Unstimulated (Basal) 237 C-peptide had the highest area under the curve (AUC), demonstrating a peak of 60% sensitivity, 238 and 100% specificity when using a cutoff of 0.38 ng/mL. Similarly, stimulated C-peptide 239 demonstrated 60% sensitivity and 100% specificity when using a cutoff of 0.725 ng/mL. There were no significant differences between responders and non-responders in terms of HbA1c 244 at the beginning (7.1 ± 0.2 % and 7.5 ± 0.2 % respectively, p-value 0.49) of the study and after 6-245 months of treatment (7.1 ± 0.3 % and 7.6 ± 0.3 % respectively, p-value 0.42). Prior to treatment 246 with dantrolene, responder subjects had higher fasting C-peptide compared to non-responders 247 (0.47 ± 0.17 ng/dL compared to 0.18 ± 0.03 ng/dL, p-value 0.03). By design, responder subjects 248 demonstrated statistically significant increases in fasting C-peptide (0.53 ± 0.17 ng/dL to 0.15 ± 249 0.006 ng/dL), stimulated C-peptide (1.20 ± 0.33 ng/dL to 0.38 ± 0.05 ng/dL p-value 0.003), and 250 ∆ C-peptide (0.67 ± 0.17 ng/dL to 0.23 ± 0.02 ng/dL p-value 0.002) after the 6-month treatment 251 period. Similar patterns were seen in between responders and non-responders when measuring 252 proinsulin, insulinogenic index, and AUC C-peptide / AUC Glucose. C-peptide to glucose ratio 253 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 12, 2020.  Table  261 S2). Of note, subject 12 had a LogMAR = 3 throughout the study period, which equates to 262 functional blindness. As a result, subject 12's data was excluded from analysis. Supplementary 263 Figure 5 demonstrates the LogMAR data including subject 12. Subgroup analyses did not 264 identify any significant differences between adult and pediatric subjects or subjects deemed to be 265 non-responders or responders. Correspondingly, subjects reported no significant improvements 266 in vision-related quality of life as measured by the NEIVFQ-25 (Supplementary Table S5 Overall disease severity was assessed in subjects prior to, and 6-months after starting dantrolene 274 treatment via WURS assessment 30 . There were no differences in total WURS disease severity, 275 or mean physician rated physical exam scores across the 6 months of the study. Subgroup 276 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 12, 2020. ; 1 5 analysis noted that pediatric subjects demonstrated statistically insignificant lower physician 277 rated WURS (3.1 ± 1.3 at baseline and 3.1 ± 1.2 after 6-months) (p-value 1.00) than adult 278 subjects (7.6 ± 1.8 at baseline and 8.8 ± 2.7 after 6-months) (p-value 0.71) (p-value 0.09 and 0.11 279 at baseline and 6-months respectively when comparing pediatric to adult subjects). Subjects 280 deemed to be responders also demonstrated statistically insignificant lower physician rated 281 WURS scores when comparing baseline (4.2 ± 1.6) and 6-months (3.2 ± 1.2) (p-value 0.62). 282 Non-responders saw a statistically insignificant increase in physician rated WURS scores when 283 comparing baseline (6.3 ± 1.6) to 6-months of treatment (7.5 ± 2.   CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Discussion 298
In this study, we evaluate the safety and tolerability of dantrolene sodium as a therapeutic 299 approach for Wolfram syndrome. Our preclinical studies show that dantrolene improves β-cell 300 and neuronal cell survival in mouse and patient iPSC models of this disease 8 . To translate these 301 findings to humans, we conducted the first clinical trial in pediatric and adult subjects with 302 Wolfram syndrome in a 6-month study of dantrolene sodium (NCT02829268). We identified a 303 tolerable range of oral dantrolene dosing of 0.5mg/kg/day to 2mg/kg/day for pediatric subjects 304 and 50mg/day to 100mg/day for adults. Overall, dantrolene was very well tolerated, and aside 305 from mild fatigue and diarrhea, no clinically significant adverse events were reported. 306 307 Admittedly, this proof of concept study ran into many of the same issues that plague early 308 clinical trials for rare diseases 21 . As the incidence of Wolfram syndrome is so rare, it is difficult 309 to recruit a large enough sample size in order to detect a statistically significant difference in 310 secondary measures of β-cell function, visual acuity, or quality of life. In order to aid with 311 recruitment, our study team collaborated with existing natural history studies and patient/parent 312 organizations. Particularly, patient/parent organizations expressed a strong desire for a potential 313 therapeutic option, as there are currently no approved treatments aimed at slowing the 314 progression of Wolfram syndrome. Through the design of the study, potential study subjects 315 lobbied strongly against a blinded or placebo-controlled study design. This helped inform our 316 decision toward an open-label phase 1b/2a design, as a positive outcome would clear a path for 317 more widespread adoption of a drug aimed at slowing the progression of Wolfram syndrome that 318 is at least proven to be safe, if not necessarily effective in all individuals. The final challenge 319 facing this study is the vast clinical heterogeneity seen in the spectrum of individuals with 320 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 12, 2020. ; https://doi.org/10.1101/2020.10.07.20208694 doi: medRxiv preprint Wolfram syndrome 31 . Independent of age, some individuals are more severely affected or 321 progress more rapidly than others. Our hypothesis is that these differences may be based on the 322 severity of the WFS1 gene variants. For example, individuals with missense mutations, may have 323 a less severe course compared to large deletions or non-sense mutations. This clinically and 324 genetically heterogeneous population makes it more challenging to infer cause and effect 325 relationships when studying a potential drug. As a result, our strategy has been to target the 326 underlying cellular defect (ER calcium depletion) that is unified amongst all patients with 327 Wolfram syndrome 32 . when looking at all subjects. However, parsing subjects by age reveals that pediatric subjects had 343 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 12, 2020. Oram and colleagues published a population-based study in the United Kingdom, demonstrating 366 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 12, 2020. ; that 8% of subjects had a urinary C-peptide-to-creatinine ratio ≥ 0.2 nmol/mmol 29 . This study 367 and another follow-up study in 2019 demonstrated that this persistent micro-secretion of C-368 peptide is associated with fewer complications of diabetes and less hypoglycemia 28 . Contrasting 369 these populations, subjects with Wolfram syndrome tend to have much higher C-peptide 370 compared to type 1 diabetes. Notably the preserved C-peptide group in the 2019 study had a 371 mean stimulated C-peptide of 114 pmol/L (0.3443 ng/mL). This is compared to a mean 372 stimulated C-peptide of 0.52 ng/mL (205 pmol/L) in our study population with Wolfram 373 syndrome. These data suggest that small, statistically insignificant, increases in C-peptide may 374 be clinically significant. Anecdotally, some of the study investigators noticed that the subject's 375 insulin needs decreased during the study, but this was not systematically evaluated in this study. 376 Additionally, many subjects wearing a continuous glucose monitors noticed more stable 377 glycemic patterns. As a result, we suggest that future studies of dantrolene or similar agents track 378 changes in total daily insulin dose (with percentage basal versus bolus) and analyze continuous 379 glucose monitor tracings (i.e. time-in-range, time-in-hypoglycemia, and standard deviation). 380 381 Similar to β-cell function, over 6 months of treatment with dantrolene sodium there were no 382 significant differences in markers of visual acuity. Markers of disease severity including WURS 383 score and other pediatric and adult quality of life measures did not significantly change over 6 384 months of treatment with dantrolene sodium. However, we noted that pediatric subjects tended to 385 have lower physician rated WURS scores compared to their adult counterparts. 386 387 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 12, 2020. We postulate that efficacy of dantrolene may be linked to the nature of the WFS1 mutations in 388 the individual subjects. Over time, and with further experience with dantrolene, perhaps 389 dantrolene can be part of a personalized medicine approach for patients with Wolfram syndrome. 390

391
In summary, this study suggests that dantrolene sodium is safely tolerated by subjects with 392 Wolfram syndrome. Although the study was small, a select few subjects seemed to have 393 improvements in β-cell function. Therefore, this study justifies further investigation into using 394 dantrolene sodium and other ER-calcium stabilizers for the treatment of Wolfram syndrome. 395 396 397 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 12, Dantrolene sodium was dispensed to the study subjects via the Washington University's clinical 419 trials pharmacy. Subjects were instructed to take the dantrolene by mouth. Subjects enrolled in 420 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 12, 2020. performed, but fasting glucose and C-peptide were obtained. An ECG was performed before and 439 4-hours after the first dose of dantrolene was administered during the run-in period, then again at 440 2-months and 6-months. Best-corrected visual acuity was assessed by Snellen optotype and 441 converted to LogMar score 33 . Vision-related quality of life was assessed in all subjects at 442 screening and after 6 months of dantrolene by the National Eye Institute's 25-item Visual 443 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 12, 2020. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 12, 2020. ; (https://www.statsmodels.org/devel/about.html#about-statsmodels) programming library. 467 Subjects who dropped out of the study or who did not complete a secondary outcome measure 468 were excluded from the analysis. Independent t-tests were performed when comparing adult to 469 pediatric subjects and non-responders to responder subjects. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 12, 2020. ;

10.
Ellis is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 12, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted October 12, 2020. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted October 12, 2020. ; https://doi.org/10.1101/2020.10.07.20208694 doi: medRxiv preprint  is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted October 12, 2020. ; https://doi.org/10.1101/2020.10.07.20208694 doi: medRxiv preprint Knee infection 1 (13) 0 (0) Tics 1 (13) 0 (0) Knee effusions 0 (0) 1 (9) Hit by car 0 (0) 1 (9) Pneumonia 0 (0) 0 (0) Otitis media 0 (0) 0 (0) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted October 12, 2020. ; https://doi.org/10.1101/2020.10.07.20208694 doi: medRxiv preprint